RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GUELI A
Collezione AO Ordine Mauriziano

Items : 29

Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients. in Hematological oncology / Hematol Oncol. 2023 Aug;41(3):335-342. doi: 10.1002/hon.3118. Epub 2022 Dec 27.

2023
AO Ordine Mauriziano
ASL Torino 4
AOU Città della Salute di Torino
AOU Novara

Tarella C; Avvedimento EV; Pileri S; Gottardi D; Cignetti A; Risso A; Bruna R; Gueli A; Derenzini E;

Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma. in Clinical radiology / Clin Radiol. 2016 Mar;71(3):271-9. doi: 10.1016/j.crad.2015.11.018. Epub 2015 Dec 31.

2016
AO Ordine Mauriziano

Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C;

Life expectancy in follicular lymphoma is mainly determined by response to first LINE treatment: A LONG-TERM survey on 597 patients in Blood

2015
AO Ordine Mauriziano

Tarella C; Gueli A; Delaini F; Barbui AM; Bruna R; Caracciolo D; Gottardi D; Gritti G; Passera R; Ramadan S; Rossi A; Rambaldi A;

Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival. in PloS one / PLoS One. 2014 Sep 25;9(9):e106745. doi: 10.1371/journal.pone.0106745. eCollection 2014.

2014
AO Ordine Mauriziano
AOU Città della Salute di Torino

Tarella C; Gueli A; Delaini F; Rossi A; Barbui AM; Gritti G; Boschini C; Caracciolo D; Bruna R; Ruella M; Gottardi D; Passera R; Rambaldi A;

Whole body magnetic resonance imaging with diffusion weighted imaging is a valuable alternative to contrast-enhanced computed tomography for the initial staging in Hodgkin's and non-Hodgkin's lymphoma in Blood

2014
AO Ordine Mauriziano

Balbo-Musetto A; Bruna R; Gueli A; Saviolo C; Petracchini M; Gottardi D; De Crescenzo A; Cirillo S; Tarella C;

Normal circulating B cells are markedly reduced in follicular lymphoma and diffuse large B cell lymphoma at diagnosis in Blood

2014
AO Ordine Mauriziano

Geuna M; Riccardo B; Cignetti A; Santoro N; Gueli A; Elia AR; Prato G; De Rosa G; Papotti M; Tarella C;

Long-term results of the phase III GITMO/FIL trial of CHOP-R versus R-HDS plus autograft in high-risk follicular lymphoma (FL) at diagnosis in Journal of Clinical Oncology

2014
AO Ordine Mauriziano

Magni M; Ladetto M; Gueli A; Passera R; Bruna R; Corradini P; Zoli V; Perrone T; Stelitano C; Rossini F; Castellino C; Gini G; Liberati AM; Musso M; Pulsoni A; Barbui AM; Patti C; Boccomini C; Benedetti F; Tarella C;

Intensified program including bendamustine, high dose therapy and autograft for patients with relapsed or resistant follicular non hodgkin lymphoma: Results from an exploratory gitil study in Hematological Oncology

2013
AO Ordine Mauriziano

Patti C; Mule' A; Barbui A; Tringali S; Costa A; Gueli A; Castellino C; Magni M; Dodero A; Leone M; Fabbiano F; Gallamini A; Corradini P; Gianni A; Tarella C; Rambaldi A; Scime' R;

Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: A case report in Blood Transfusion

2013
AO Ordine Mauriziano

Tarella C; De Crescenzo A; Ricca I; Hu H; Gottardi D; Gueli A;

The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy in American Journal of Hematology

2013
AO Ordine Mauriziano

Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C;

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma in Annals of Hematology

2013
AO Ordine Mauriziano

Ferrero S; Monitillo L; Mantoan B; Barbero D; Genuardi E; Barbiero S; Bernocco E; Caracciolo D; Ruella M; Drandi D; Zanni M; Renna F; Lobetti Bodoni C; Gueli A; Passera R; Musto P; Boccadoro M; Tarella C; Ladetto M;

Frequency and clinical outcome of primary refractory disease in nonhodgkin's lymphoma: A retrospective survey on 3,492 newly diagnosed patients undergoing first-line chemotherapy in Haematologica

2013
AO Ordine Mauriziano

Tarella C; Gueli A; Delaini F; Rossi A; Barbui A; Gritti G; Caracciolo D; Hu H; Gottardi D; Passera R; Rambaldi A;

Telomere loss is an early and persistent abnormality in leukocytes from patients treated with conventional chemotherapy but not from those exposed to rituximab alone in Haematologica

2013
AO Ordine Mauriziano

Gueli A; Risso A; Spatola T; Hu H; Gottardi D; De Crescenzo A; Buttiglieri S; Tarella C;

Lymphocyte transformation and autoimmune disorders in Autoimmunity Reviews

2013
AO Ordine Mauriziano

Tarella C; Gueli A; Ruella M; Cignetti A;

Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: A case report in Blood Coagulation and Fibrinolysis

2012
AO Ordine Mauriziano

Wade M; Tarella C; Hu H; Gueli A; Ruella M; Sivera P;

Primary refractory disease in non-Hodgkin's lymphoma: A retrospective study on 3,952 newly diagnosed patients undergoing first-line chemotherapy in Blood

2012
AO Ordine Mauriziano

Tarella C; Gueli A; Delaini F; Rossi A; Barbui AM; Gritti G; Caracciolo D; Hu H; Gottardi D; Passera R; Rambaldi A;

The peripheral blood lymphocyte to monocyte ratio at diagnosis is a potent outcome predictor in diffuse large B-cell lymphoma treated with R-CHOP: A long-term analysis on 973 patients receiving chemotherapy with or without rituximab in Blood

2012
AO Ordine Mauriziano

Rambaldi A; Boschini C; Delaini F; Oldani E; Rossi A; Barbui AM; Gritti G; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Gianni AM; Tarella C;

Circulating non-leukemic b cells and b cell subsets are altered in B cell non-hodgkin lymphoma patients in Cytometry Part B - Clinical Cytometry

2012
AO Ordine Mauriziano

Geuna M; Prato G; Santoro N; Gueli A; Tarella C; Cignetti A;

Early and persistent telomere shortening in leukocytes from patients treated with conventional chemotherapy but not from those exposed to rituximab alone in Haematologica

2012
AO Ordine Mauriziano

Gueli A; Risso A; Ruella M; Spatola T; Hu H; Gottardi D; De Crescenzo A; Buttiglieri S; Tarella C;

Role of whole body magnetic resonance including diffusion weighted imaging in the initial staging of lymphoma in Haematologica

2012
AO Ordine Mauriziano

Tarella C; Cirillo S; Hu H; Gueli A; Ruella M; Petracchini M; Gottardi D; Lario C; De Crescenzo A; Balbo-Mussetto A; Saviolo C;

Pre-emptive rituximab-based treatment of molecular relapses in follicular and mantle cell lymphoma in Haematologica

2012
AO Ordine Mauriziano

Ferrero S; Monitillo L; Mantoan B; Barbero D; Genuardi E; Bruna R; Bernocco E; Caracciolo D; Ruella M; Drandi D; Zanni M; Gueli A; Renna F; Ghione P; Lobetti Bodoni C; Barbiero S; Musto P; Boccadoro M; Tarella C; Ladetto M;

Early and permanent telomere shortening in bone marrow-derived cells following chemotherapy: A parallel study in vivo in lymphoma patients and in vitro in cultured mesenchymal stem cells in Blood

2011
AO Ordine Mauriziano

Gueli A; Ruella M; Risso A; Spatola T; Hu HJ; Gottardi D; De Crescenzo A; Buttiglieri S; Tarella C;

Efficacy of lenalidomide as single agent to control minimal residual disease in chronic lymphocytic leukemia in first complete remission in Haematologica

2011
AO Ordine Mauriziano

Ruella M; De Crescenzo A; Gottardi D; Prato G; Geuna M; Gueli A; Tarella C;

Telomere shortening is an early aging sign following exposure to cytotoxic drugs: Assessment both in vitro on cultured mesenchymal stem cells and in vivo on cells from patients undergoing chemotherapy in Haematologica

2011
AO Ordine Mauriziano

Risso A; Buttiglieri S; Gueli A; Spatola T; Avvedimento EV; De Crescenzo A; Gottardi D; Mezzabotta M; Ruella M; Tarella C;

Male gender, quality of grafted cells, advanced age, rituximab and radiotherapy are the main factors that variously influence the occurrence of secondary malignancies following high-dose therapy and autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) survey in 1,347 lymphoma patients in Blood

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Passera R; Magni M; Rossi A; Benedetti F; Gueli A; Patti C; Parvis G; Ciceri F; Gallamini A; Cortelazzo S; Corradini P; Zoli V; Mule A; Crocchiolo R; Bosa M; Barbui A; Di Nicola M; Caracciolo D; Sorio M; Gianni AM; Rambaldi A;

Dexamethasone, cytarabine and cisplatin or oxaliplatin schedule (DHAP or OX-DHA) is effective and widely applicable in chronic lymphocytic leukemia and waldenström macroglobulinemia in Blood

2009
AO Ordine Mauriziano

Ruella M; Ricca I; Gueli A; Gottardi D; Caracciolo D; Bergui L; Gavarotti P; De Crescenzo A; Farina L; Corradini P; Tarella C;

High response rate with favorable survival projections in high-risk patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP-14 or early intensified chemotherapy with rituximab and autograft (R-HDS): Results of the interim analysis of a gitil prospective multicenter phase III study in Blood

2009
AO Ordine Mauriziano

Cortelazzo S; Tarella C; Gianni AM; Ladetto M; Zanni M; Corradini P; Di Nicola M; Patti C; Mulè A; Majolino I; Billio A; Gueli A; Di Raimondo F; Chiarenza A; Gallamini A; Ferreri A; Pizzolo G; Benedetti F; La Nasa G; Leoni P; Gini G; Trentin L; Rodeghiero F; Marchioli R; Barbui T; Barbui A; Rambaldi A;

Factors influencing the occurrence of secondary myelodysplastic syndrome/acute leukemia following high-dose therapy and autograft: A GITIL (Gruppo Italiano Terapie innovative nei linfomi) survey in 1,347 lymphoma patients in Haematologica

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Passera R; Magni M; Rossi A; Gueli A; Benedetti F; Patti C; Parvis G; Ciceri F; Gallamini A; Cortelazzo S; Corradini P; Zoli V; Leone M; Bosa M; Barbui A; Di Nicola M; Boccadoro M; Sorio M; Gianni AM; Rambaldi A;

Modified DHAP schedule containing oxaliplatin (OX-DHA) is effective and widely applicable in Chronic Lymphocytic Leukemia and Waldestrom disease in Haematologica

2009
AO Ordine Mauriziano

Ricca I; Ruella M; Gueli A; Gottardi D; Caracciolo D; Bergui L; Gavarotti P; Boccadoro M; Tarella C;